A series of 5-halo derivatives of the anti-human immunodeficiency virus (HIV) nucleoside analogue d4T have been prepared by a general and highly stereoselective route. A key step is the electrophilic addition of N-iodosuccinimide to furanoid glycals. The 2'·iodo nucleosides thus obtained produced the corresponding 2' ,3'-didehydro-2',3'-dideoxynucleoside in a two-step elimination reaction upon treatment with potassium tbutoxide followed by sodium methoxide. The derivatives were tested for their ability to inhibit the replication of HIV-1 and HIV-2 in cell culture. Replacement of the thymine 5-methyl group of the parent nucleoside analogue (d4T) by I, CI or F resulted in compounds that showed poor antiviral activity. In view of this, we studied the application of blocked phosphate (phosphoramidate) technology to probe the efficacy of intracellular monophosphate delivery in these systems. In one case, significant antiviral potency was obtained in this way.
Introduction
Dideoxydidehydrothymidine (d4T; 1) is a potent inhibitor of the replication of human immunodeficiency virus (HIV) and is used in the clinic for the treatment of HIV infection (Baba et al., 1987; Balzarini et al., 1987) . It is the archetypal member of the dideoxy didehydro (d4) nucleoside family. Current methods for the synthesis of d4 nucleosides are based on modification of natural nucleosides by altering the 2' and/or 3' hydroxyl groups (Mansuri et al., 1989; Robins et al., 1995) . In our case, to prepare these nucleosides we have focused on a convergent approach, since this can be used in the synthesis of a wide variety of structurally related compounds (Fig. 1) . Previously, several efforts to prepare d4 nucleosides starting from synthetic sugars suffered from poor selectivity in the glycosidation step (Abdel-Megied et al., 1991; ]ung & Gardiner, 1992) . More recently, regiospecific and highly stereoselective electrophilic addition reactions to furanoid glycal intermediates have been described (Kim & Misco, 1992; Kawakami et al., 1993) . This approach (Kim & Misco, 1992) involves an iodine-mediated introduction of the base to give~-nucleosides and then bimolecular elimination of HI as well as sugar deprotection, to afford the desired nucleosides.The high stereoselectivity observed in this reaction is a consequence of the sterically favoured aface approach of the electrophile. The resulting a-halonium ion is then attacked from the~-face by the silylated base to give the~-nucleoside as a major product. This strategy has been used recently for the synthesis of d4T (Kim & Misco, 1992; McDonald & Gleason, 1995) . We herein report the extension of this approach to other bases. In particular, a number of 5-halo-substituted bases are employed to give several 5-halo d4 nucleosides, which are evaluated as antiviral agents. There is a long history of 5halo nucleosides showing antiviral (Prusoff, 1959; Van Aerschot et al., 1989) and anticancer (Danenberg, 1977) properties, and we were keen to apply our improved synthesis of d4 nucleosides to these analogues. Our general method to 5-halo d4 nucleosides differs, and improves in terms of~-selectivity in the glycosidation reaction, from that recently developed by another group (Larsen et al., 1995) involving condensation between a 3- Pure~-anomers:
(Sa) X =F;68%
(Sb) X = CI; 57%
(ScI X = I; 52%
• [e3C_~-~J---.. Furthermore, we have recently introduced a phosphoramidate technology which allows the intracellular delivery of free nuc1eotides. Since this method proved very effective for d4T we applied it to the 5-halo analogues described herein (McGuigan et al., 1996a; Balzarini et al., 1996) .
Materials and Experimental Procedures: Chemistry
IH, 13C, 3Ip and I9F NMR spectra were recorded in a Bruker AVANCE DPX300 spectrometer. AllIH and I3C NMR chemical shifts (b) are quoted in p.p.m. downfield from tetramethylsilane. All3Ip and I9F chemical shifts are quoted in p.p.m. using H 3P04 and C 6F6 as external reference, respectively. Mass spectra were recorded on a Fisons VGn Platform spectrometer and the mode of ionization, unless otherwise stated, was electrospray (ESMS), with a mobile phase of acetonitrile: water 1 : 1, and a flow rate of 4 mL min-I with a Pharmacia LC pump. All analytical HPLC experiments were done on an ACS 350/04 system provided with an ACS 351/04 gradient controller and using an ACS 750/12 detector set at 254 nm. The systems used were: Ultratech50DS (2Sx4.6 mm) reverse phase column. Mobile phase: isocratic conditions, 55/45 acetonitrile/water. Flow was 1.0 mL min'", All retention times are quoted in min.
Separations on silica gel were performed by preparative centrifugal circular thin layer chromatography (CCTLC) on a chromatotron instrument o(Kiesegel 60PF254, Merck). Layer thickness, 1 rnrn. Dichloromethane, methanol, triethylamine and pyridine were dried over calcium hydride and distilled at atmospheric pressure. Tetrahydrofuran was dried over sodiumlbenzophenone and distilled under nitrogen. All other solvents and reagents were used as supplied.
(5)-(+)-yPivaloyloxymethyl-ybutyrolactone
A solution of (S)-(+)-yhydroxymethyl-ybutyrolactone (2) (0.95 g, 8.18 mmol) and pivaloyl chloride (1.2 mL, 9.81 mmol) in dry pyridine (20 mL) was heated to 50°C for 4 h. The solvent was evaporated to dryness and co-evaporated twice with toluene. The residue was taken in CHCI (30 mL) and washed with 1 M HCI (30 mL), water (30 mL) and brine (30 mL). Purification of the residue by column chromatography (petroleum ether: ethyl acetate 2:1) gave 1.35 g of an oil (88%). [a oF6=+26.4 D (c=l, CHCl 3 ) . IH NMR (CDCl 3 ) 4.83 (lH, m, H-4), 4.39, 4.20 (2H, m, 2H-5,j4S=4.3, 6. (5S)-5-(pivaloyloxy)methyl-4,5-dihydrofuran (3) A 1.5 M Dibal-H solution in toluene (2.31 mL, 3.49 mmol) was added dropwise over 15 min to a stirred solution of (S)-(+)-ypivaloyloxymethyl-ybutyrolactone (0.6 g, 3.18 mmol) in 24 mL of dry THF at -78 DC under nitrogen for 2 h. The reaction was quenched with MeOH, diluted with EtOAc, poured into 0.2 M HCl and extracted twice with CH 2Cl2. The combined extracts were washed with NaHC0 3 , water, dried and concentrated to give an oily residue (0.57 g). The crude lactol was taken up in CH 2Cl2 (12 mL), cooled to -20 DC under nitrogen and treated with Et 3N (1.25 mL, 9 mmol) followed by mesyl chloride (0.38 mL, 3.9 mmol) for 30 min. The resultant white suspension was stirred at reflux for 5 h and then diluted with CH 2Cl2, washed with water, dried (Na 2S04) and concentrated, affording a brown oil. The crude material was chromatographed (CH 2CI;: MeOH, 100:1) to give 0.25 g (45%) of 3. [a oF 6=+56.8 D (c=l, EtOH); Lit.
[a oF6=+85.4 D (c=1.46, CHCI 3 ) (Takle & Kocienski, 1990) . IH NMR (CDPD) 6.30 (lH, q, H-1,]=2.5 Hz) 
General procedure for glycosidation via a furanoid glycal intermediate
To a stirred mixture of the corresponding heterocyclicbase (1.39 mmol) in dry CH 2Cl2 (10 mL) two equivalents of N,O-bis (trimethylsilyl)acetamide (2.78 mmol) were added and the mixture was heated to reflux until the solution became clear (around 1 h). After cooling to room temperature a solution of the furanoid glycal 3 (0.20 g, 1.16 mmol) in CH 2C12 (2 mL) and approximately300 mg of 4 A powdered molecular sieves were added to the solution. The resulting mixture was stirred for 15 min at room temperature, cooled to -20 DC and then N-iodosuccinimide (0.313 g, 1.39 mmol) was added. After being stirred for 1 h; the mixture was filtered and ethyl acetate (50 mL) and 10% aqueous Na 2S203 (50 mL) was added. The organic phase was removed and the aqueous phase was extracted with ethyl acetate (2x50 mL). The combined organic phases were dried (MgS0 4 ) and concentrated. The residue was purified by column chromatography (hexane: ethyl acetate, 1:1) to give the corresponding 2'iodonucleosides. Antiviral Chemistry & Chemotherapy 8(6) 5-halo 2',3'-dideoxynucleosides
1-(2',3'-dideoxy-2'-iodo-5'-O-(pivaloyl)-f3 and a-D-ribofuranosyl) 5-fluorouracil 4a
Via the general procedure, 5-fluorouracil (0.19 g, 1.39 mmol) was silylated for 1 h and then treated with the glycal (0.20 g, 1.16 mmol) and N-iodosuccinimide (0.313 g, 1.39 mmol) for 1 h. The residue, a mixture lOll of thẽ /a anomers (determined by IH NMR), was purified by column chromatography (hexane: ethyl acetate, 1:1) to yield a mixture of~and a-anomers (4a) as a yellow foam (0.25 g, 57%). IH NMR (CDCI 3 ) 8.55 (2H, bs, NHa,~), 7.78 (lH, d, H-6P, lr,H-6=5.9 Hz), 7.26 (lH, d, H-6a) 6.19 (lH, dd, H-1'~,Jl'.2"1,,F=1.7, 1.9 Hz), 6.11 (lH, d, H-1'a,]1'.2,=6.8 Hz), 4.77-4.11 (8H, m, 2H-2'a,~, 2H-4'a,~, 4H-5'a,~), 2.36-2.08 (3H, m, H-3'a, 2H-3<PRI~), 1.25 (9H, s, 3-Meb), 1.23 (9H, m, 3-Mea). MS(ES+) 463 (M+Na).
1-(2',3'-dideoxy-2'-iodo-5'-O-(pivaloyl)-f3 and a-D-ribofuranosyl) 5-chlorouracil 4b
According to the general procedure, 5-chlorouracil (0.41 g, 2.79 mmol) was silylated for 1 h and then reacted with the glycal (0.40 g, 2.32 mmol) and N-iodosuccinimide (0.57 g, 2.55 mmol) for 1 h. The residue, a mixture 8/1 of the~/a anomers (determined by IH NMR), was purified by column chromatography (hexane: ethyl acetate, 1:1). to give a mixture of the~-and a-isomers (4b) 
1-(2',3'-dideoxy-2'-iodo-5'-O-(pivaloyl)-'f3-and o-o-riboturenosyl) 5-iodouracil 4c
According to the general procedure, 5-iodouracil (0.41 g, 1.74 mmol) was silylated for 1 h and then reacted with the glycal (0.25 g, 1.45 mmol) and N-iodosuccinimide (0.39 g, 1.74 mmol) for 1 h. The residue, a mixture 8/1 of the~Ia anomers (determined by IH NMR), was purified by column chromatography (hexane: ethyl acetate, 2:1) to give a mixture of the~-and a-isomers (4c) 
1-(2',3'-dideoxy-5'-pivaloyl-f3-D-glycero-pent-2enofuranosyl)-5-fluorouracil Sa
A solution of the iodonucleoside (4a) (0.14 g, 0.318 mmol) in dry THF (4 mL) was reacted with tBuOK (0.072 g, 0.636 mmol) at O°C for 1 h. The reaction was diluted with ethyl acetate and then washed successively with 1 M HCI, 5% NaHC0 3, water and brine. The dried (MgSO4) organic layer was concentrated under reduced pressure and the residue was purified by chromatotron (hexane:ethyl acetate, 1:1). The fastest moving fractions gave the 13 anomer (5a) as a white foam (0.067 g, 68%). lH NMR (CDCI 3) 9.51 (lH, bs, NH), 7.55 (lH, d, H-6,]H_6,F=5.7 Hz), 6.96 (lH, m, H-1'), 6.30 (lH, m, H-3'), 5.96 (1H, m, H-2'), 5.08 (lH, m, 4.53 (lH, m, J 4', 5, =4.1, J 5', 5, =12.7 Hz), 4.19 (lH, m, J 4', 5, =2.8 
1-
This was prepared by a method entirely analogous to that used for Sa above except that the reaction was stirred for 1.5 h. The residue was purified by chromatotron (hexane:ethyl acetate, 1:1). The first fractions gave the 13 anomer (Sb) as a white foam (57%). 'H NMR (CDCl 3) 8.48 (lH, bs, NH), 7.66 (lH, s, H-6), 6.94 (lH, m, H-1'),6.33 (lH, m, H-3'), 6.00 (lH, m, H-2'), 5.13 (lH, m, H-4'), 4.58 (lH, m, H-5',J4'5,=4.3,J 5'5,=12.6 
This was prepared by a method entirely analogous to that used for Sa above except that the reaction was stirred for 1.5 h. The residue was purified by chromatotron (hexane:ethyl acetate, 1:1). 
This was prepared by a method entirely analogous to that used for 6a with a yield of 89%. lH NMR ( 
Phenyl methoxyalaninyl phosphorochloridate (0.574 mmol, 2.0 equiv)was added to a stirred solution of 6a (65 mg, 0.287 mmol) and N-methylimidazole (137 mL, 1.72 mmol, 6 equiv) in dry THF (2 mL) at ambient temperature. After 2 h water was added and the solvent removed under pressure. The residue was dissolved in CHCl 3 (10 mL), washed with 1 M HCI (10 mL), water (10 mL) and brine (10 mL). The organic phase was dried (MgSO4) and the solvent removed in vacuo. The residue was purified by chromatotron (CH 2CI2 : MeOH, 20:1) to give (7a) SV2b64 (105 mg, 78%) as a white foam. 
1-(2',3'-dideoxy-5'-(phenylmethoxyalaninylphosphate)-{3-o-glycero-pent-2-enofuranosyl fluorouracil 7b
This was prepared by a method entirely analogous to that used for 7a above, except that the reaction was stirred for 2 h.
Yield 72% 
1-(2',3'-dideoxy-5'-(phenylmethoxyalaninylphosphate)-{3-o-glycero-pent-2-enofuranosyl) iodouracil 7c
This was prepared by a method entirely analogous to that usedfor 7a above, except that the reaction wasstirredfor 3 h.
Yield 79%.31P NMR 4.62, 4.34 (1:1). 1H NMR (CDCI 3) 8. 70, 8.68 (lH, bs, NH), 7.98, 7.95 (1H, s, , Antiviral Chemistry &Chemotherapy 8(6) 5-halo 2',3'·dideoxynucleosides 7. m, Ph), 7.00, 6.97 (1H, m, 6.43, 6.35 (lH, m, 5.99, 5.91 (lH, m, 5.11 (1H, m, 4.40 (2H, m, , 4.14 (IH, m, Ala-Cl-l), 3.78 (IH, m, Ala-NH), 3.76, 3.76 (3H, s, Ala-OCH 3), 1.45, 1.41 (3H, d, Ala-CH 3,1=7.0, 7.1 Hz). l3C NMR (CDCI 3) 173. 733, 173.62 (m, C0 2Me), 159.65, 159.56 (C-4), 150.37, 150.28, 150.05 (C-2, Phipso), 14481, 144.65 (C-6), 133.78, 133.66 (C-3'), 129.76, 129.63 (Phmeta), 127.02, 126.81 (C-2'), 125.18 (Phpara), 120.43, 120.36, 120.23, 120.16 (d, Phorto,1p,c=5.0, 4.9 Hz), 90.19, 90.15 (C-l'), 85.39, 85.26, 85.15 (d, C-4', Ip,c=9.6, Hz), 68.89, 68.75 (C-5), 66.92, 66.84, 66.36 (d, C-5',}p,c=5,4 
Materials and Experimental Procedures: Virology
HIV-l strain IIIB was obtained from RC Gallo (at that time at the National Cancer Institute, National Institutes of Health, Bethesda, Md., USA). HIV-2 ROD was provided by L Montagnier (Pasteur Institute, Paris, France). CEM/O cells were obtained from the ATCC (Rockville, Md., USA), and CEMITK-cells were a kind gift from S Eriksson and A Karlsson (Karolinska Institute, Stockholm, Sweden). CEM cellswere infected with HIV-1 as previously described (Balzarini et al., 1993) . Briefly, 4xlO s CEM cells mL-1 were infected with HIV-l or HIV-2 at 100 CCID so (50% cell culture infective dose) per mL of cell suspension.Then, 100 I-lL of the infected cell suspension was transferred to microtitre plate wells and mixedwith 100 I-lL of the appropriate dilutions of the test compounds. After 4 days, giant cell formation was recorded microscopically in the HIV-infected cellcultures. The 50% effective concentration (EC so) and 50% cytotoxic concentration (CC so) were defined as the compound concentrations required to reduce by 50% the number of giant cells in the virus-infected cell cultures, and the number of viable cells in the mock-infected cell cultures, respectively.
Results
The requisite furanoid glycal was prepared following a literature procedure (Takle & Kocienski, 1990 ) from the known lactone (2) which is commercially available or easily synthesized from L-glutamic acid (Taniguchi et al., 1974) . As shown in the scheme, compound 2 was converted to the glycal (3) by the three-step sequence; esterification with pivaloyl chloride, reduction of lactone with Dibal-H, and mesylation of the lactol and subsequent elimination of the mesyl group to give 3.
The first pyrimidine base to be investigated was 5-fluorouracil. Silylation of this base with bis-trimethylsilylacetamide was carried out prior to the nucleoside coupling reaction. As shown in the scheme, silylated 5fluorouracil was then condensed with 3 in dry dichloromethane using N-iodosuccinimide and 4 A molecular sievesto afford 4a (57%) as an anomeric mixture where the desired (3-isomer was the major product. The ratio (3 : a was determined as 8 : 1 by 1H NMR on the crude product. The iodonucleosides (4a) proved to be stable to silica gel chromatography but the anomers could not be separated at this stage. Some starting material (10%) was also recovered from the reaction. However, longer reaction times (2-3 h) did not improve the yield of the anomeric mixture. It was noted that the addition of 4 A molecular sieves is very important for the reaction, preventing decomposition from occurring, as observed by TLC.
In a similar fashion, other silylated bases were condensed with 3 to give the 2'-halo nucleosides (4b-c) in moderate yields and with a high degree of stereoselectivity. In all cases variable amounts (10-15%) of the starting material were recovered. J 1 '.2' coupling constant values of the major and minor 2'-halo nucleoside isomers were in the range 1.9-3.8 and 6.6-7.2 Hz which correspond to the (3-and o-anomers, respectively. This is in agreement with the stereochemical result reported for the d4T synthesis (Kim &Misco, 1992; McDonald & Gleason, 1995) .
The next step in the synthetic reaction was the basepromoted elimination of hydrogen iodide from the 2'-iodonuc1eosides to give the desired 2',3'-didehydro-2',3'-dideoxynucleosides. A literature procedure (Kim & Misco, 1992) involved the initial conversion of the 2'- Table 1 . Antiviral activity of synthesized compounds iodonucleoside into the corresponding 2,2'-anhydro compound by treatment with DBU, followed by basecatalysed hydrolysis with potassium t-butoxide (1 equivalent) in THF, and final pivaloyl deprotection with sodium methoxide in methanol. In a second procedure (Kim & Misco, 1992; McDonald & Gleason, 1995) the iodonucleoside is converted into the d4 compound in only one step by using a large excess of sodium methoxide in methanol.
Initial attempts were made using the latter one-step procedure. However, treatment of either crude or purified anomeric mixture (4a) with 5-60 equivalents of a freshly prepared solution of sodium methoxide invariably resulted in glycosidic cleavage even after 10 min of reaction. This result contrasts with the literature procedure described above. However, treatment of the anomeric mixture (4a) with two equivalents of potassium t-butoxide in dry THF at O°C for 1 h gave the desired 5-fluoro-2',3'-didehydro-2',3'-dideoxynucleoside analogue. This anomeric mixture was separated by chromatotron to give pure (3-anomer(5a). Thus, we found that potassium t-butoxide elimination is a good alternative to the two-step elimination (DBU-tBuOK) described in the literature (Kim & Misco, 1992) . Subsequent removal of the pivaloyl protecting group with one equivalent of sodium methoxide in methanol afforded the desired unprotected d4 derivative (6a) in high yield (90%), with no glycosidic decomposition observed.
The two-step procedure developed· above was now applied to other pyrimidine bases.Thus, similar treatment of the anomeric mixtures (4b-c) with two equivalents of potassium t-butoxide gave the protected d4 nucleosides (5b-c) in good yields. The (3 and a anomers were separated by chromatotron at this stage, and deprotection of (5b-c) with one equivalent of sodium methoxide afforded the desired d4 nucleosides (6b-c) in high yields. The 1H and 13C NMR data on 6a, 6b and 6c are in close agree- rnent with data in the literature (Joshi et al., 1992; Khwaja & Heidelberger, 1967; Coe et al., 1994; Van Aerschot et al., 1990) further confirming the integrity of the B-stereochemistry in these compounds. Following our published procedures (McGuigan et al., 1996a) we converted each of the free nucleosides (6a-c) to their protected phenyl methoxyalaninyl phosphates, as potential membrane-soluble prodrugs for their free phosphate forms. This particular blocked phosphate has been optimized for the delivery of d4T monophosphate (McGuigan et al., 1996b, c) . Purification by chromatotron gave the three new phosphates (7a-c) in around 70-80% yield; full spectroscopic-and analytical data confirmed the structure and purity of these materials.
Discussion
Each of the nucleosides (5a-c) and (6a-c) and the phosphates (7a-c) were tested for their ability to inhibit the replication ofHIV-1 and HIV-2 in cell culture.The reference compound d4T (1) was included as a positive biological control, and assays were conducted in two cell lines, wild-type CEM/O and CEMITK-, the latter being deficient in thymidine kinase activity and thus being poorly responsive to the biological effects of d4T. As noted in Table 1 , apart from d4T (1), all of the nucleosides tested displayed poor antiviral activity. Indeed, no appreciable inhibition of viral replication was noted for any compound (5a-c) or (6a-c) at non-cytotoxic concentrations. Little difference in the biological profile was noted for the 5'protected series (5a-c) versus the 5'-unprotected compounds (6a-c), and no trends could be discerned within each series by changing the 5-halogen group, with the possible exception that the 5-fluoro compounds (5a, 6a) appeared to be somewhat more cytotoxic than the 5chloro and 5-iodo compounds.
The lack of significant antiviral activity of the compounds herein reported is surprising, in view of the high potency and selectivity of the parent nucleoside analogue d4T (1). There is a >50-to >300-fold reduction in anti-HIV-1 activity of d4T upon replacement of the thymine 5-methyl group by a halogen atom. This is especiallysurprising given the antiviral potency (Prusoff, 1959) of 5-iodo-2'-deoxyuridine (IDU), where a 5-methyl group is similarly replaced by an iodine atom. However, this is in the case of anti-herpesvirus activity, whilst the current study concerns exclusively anti-HIV activity. The relatively high cytotoxicity noted for IDU indicates its efficient phosphorylation by host thymidine kinase (TK), whilst the relative biological inertness of, in particular, 6c may indicate that TK cannot (or can only poorly) activate this d4 analogue. Thus, the host cell TK which activates IDU and d4T may not activate the chimeric analogue 6c. Antiviral Chemistry & Chemotherapy 8(6) 5-halo 2',3'·dideoxynucleosides Alternatively, the nucleoside 6c may be activated by TK to the monophosphate, but may then be poorly processed to the putative bio-active triphosphate by nucleotide kinases and/or the triphosphate may be non-inhibito-ry to both HIV reverse transcriptase (RT) and host cell DNA polymerases. Thus, it was of particular interest to apply our recently introduced kinase bypass technology to the poorly active nucleoside analogues (6a-c). In this method, lipophilic blocked phosphates act as membrane soluble prodrugs for the free 5'-monophosphate (McGuigan et al., 1993a) . We have found that phosphoramidates, notably those derived from blocked amino acids, are particularly effective, at least in the case of d4T (McGuigan et al., -·1996a,b, 1997a Balzarini et al., 1996) . Thus, it is particularly interesting to note (Table  1 ) that both the chloro compound (7b) and the iodo compound (7c) show significant antiviral action as their blocked phosphates, whilst both compounds are inactive as their free nuc1eosides (6b, 6c). The 5-chloro case is particularly striking; here the blocked phosphate (7b) emerges as a sub-micromolar anti-HIV agent, with a selectivity index of around 300. Furthermore, it is notable that this compound (and to some extent the 5-iodo analogue 7c) retains full activity in the TK-deficient cell line CEM/TK-. This strongly implies that the antiviral action of (7b) arises from the intracellular delivery of the free 5'-monophosphate, thus bypassing the dependence on cellular TK. This is entirely the mechanism we have noted for the analogous blocked phosphoramidate of d4T (Balzarini et al., 1996) and fully supports the suggestion that the 5-halo d4 nucleosides, particularly the 5-chloro compound (6b), are inactive due to poor phosphorylation by cytosolic TK. We regard this as a further example of the concept we have introduced of 'kinase bypass', wherein inactive nuc1eosides, whose inactivity arises due to poor nucleoside kinase-mediated phosphorylation, may be activated by the formation of a suitable blocked phosphate (McGuigan et al., 1993b) . We are now actively investigating the possibilities and limitations of this bypass technology. In particular, it may be that other 5-substituents might be more effective than the chloro group herein reported; the bromo compound is a clear early target, besides compounds with other (non-halo) groups.
